Open | - |
Close | - |
Volume / Avg. | 0 / 23.426K |
Day Range | - - - |
52 Wk Range | 2.510 - 4.550 |
Market Cap | $24.170M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 52 |
Short Interest | 5.19% |
Days to Cover | 13.39 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Lumos Pharma (NASDAQ: LUMO) through any online brokerage.
Other companies in Lumos Pharma’s space includes: Galecto (NASDAQ:GLTO), OncoCyte (NASDAQ:OCX), T2 Biosystems (NASDAQ:TTOO), Sensei Biotherapeutics (NASDAQ:SNSE) and NuCana (NASDAQ:NCNA).
The latest price target for Lumos Pharma (NASDAQ: LUMO) was reported by Oppenheimer on Friday, March 8, 2024. The analyst firm set a price target for 16.00 expecting LUMO to rise to within 12 months (a possible 436.68% upside). 12 analyst firms have reported ratings in the last year.
The stock price for Lumos Pharma (NASDAQ: LUMO) is $2.9813 last updated March 12, 2024 at 4:55 PM EDT.
There are no upcoming dividends for Lumos Pharma.
Lumos Pharma’s Q1 earnings are confirmed for Wednesday, May 1, 2024.
There is no upcoming split for Lumos Pharma.
Lumos Pharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.